Eric Widera, MD: I’ll never understand how a study like this gets through peer review. While GLP-1RA & SGLT2i meds are pretty amazing, they can’t decrease risk for dementia the moment you get a prescription. That’s a clear signal that the groups are different at baseline. #medsky jamanetwork.com/journals/jam...

I’ll never understand how a study like this gets through peer review. While GLP-1RA & SGLT2i meds are pretty amazing, they can’t decrease risk for dementia the moment you get a prescription. That’s a clear signal that the groups are different at baseline. #medsky jamanetwork.com/journals/jam...